Shopping Cart 0
Cart Subtotal
USD 0

Jubilant Life Sciences Ltd (JUBILANT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company's product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical ingredients (APIs), solid dosage formulations, life science chemicals, nutritional products, fine ingredients, advance intermediates and crop science ingredients. It also provides contract manufacturing of sterile injectables and drug discovery and development services. The company caters its products and services to customers across India, North America, Canada, Europe and China. It owns and operates cGMP compliant manufacturing facilities, and research and development centers in India, the US and Canada. Jubilant is headquartered in Noida, Uttar Pradesh, India.

Jubilant Life Sciences Ltd (JUBILANT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Jubilant Pharma Plans to Acquire Pharma Business in US 14

Partnerships 15

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16

Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17

Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18

Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19

Licensing Agreements 20

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20

TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21

Equity Offering 22

Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22

Debt Offering 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24

Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25

Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26

Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27

Jubilant Life Sciences Plans Debt Offering For USD 250 Million 28

Asset Transactions 29

Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29

Acquisition 30

Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30

General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31

Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32

Jubilant Life Sciences Ltd-Key Competitors 33

Jubilant Life Sciences Ltd-Key Employees 34

Jubilant Life Sciences Ltd-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 38

Financial Announcements 38

Oct 22, 2018: Jubilant Life Sciences: Q2 & H1 'FY19 Results 38

Jul 27, 2018: Jubilant Life Sciences- Q1 FY 2019 Results-Jubilant Reports Strong Performance in Q1'FY19 Revenue at Rs. 2,079 Crore, up 34% YoY 42

May 09, 2018: Jubilant Life Sciences-Q4/ FY2018 Results- Jubilant Reports Strong Performance in Q4'FY18 Revenue at Rs. 2,252 crore, up 41% YOY; EBITDA at Rs. 481 crore, up 52% YOY PAT at Rs 155 crore 45

Jan 17, 2018: Jubilant Reports Record Performance In Q3 FY2018; Highest Ever Revenues And Profits Revenue At Rs. 2,068 Crore, Up 42% YOY and Ebitda at Rs. 431 Crore, Up 28% YOY Pat At Rs. 213 Crore, Up 78% YOY With 49

Oct 28, 2017: Jubilant Life Sciences: Q2/H1 FY2018 Results 53

Jul 18, 2017: Jubilant Life Sciences: Q1 FY2018 Result 57

Jul 18, 2017: Jubilant Reports Q1 FY2018 Revenue of Rs. 1,596 Crore, UP 10% YOY Pharma Segment Records Highest Ever Sales Ebitda of Rs. 344 Crore and Margins of 21.6%; Pat of Rs. 147 Crore 59

May 23, 2017: Jubilant Life Sciences Reports Total RevenueOf INR26.2 Billion In Fiscal 2017 61

Feb 07, 2017: Jubilant Reports Strong Performance In Q3 FY17; Sales At Rs. 1,492 Crore, Up By 7% YOY EBITDA At Rs. 337 Crore; Up 9% YOY With Margins Of 22.6%; PAT At Rs. 120 Crore 62

Corporate Communications 65

Oct 22, 2018: Jubilant Life Sciences announces appointment of directors 65

Jan 17, 2018: Jubilant Life Sciences: Changes in the Board of Directors 66

Legal and Regulatory 67

Mar 04, 2018: Jubilant Life Sciences: Commissioner of State Excise Cancelled License DS-1 License and Form-I License relating to the Distillery operations 67

Jan 25, 2017: Jubilant Life Sciences is now Responsible Care 14001: 2013 certified 68

Other Significant Developments 69

Jun 01, 2017: Jubilant Life Sciences Provides Update on Gajraula Manufacturing Unit 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Jubilant Pharma Plans to Acquire Pharma Business in US 14

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16

Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17

Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18

Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20

TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21

Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22

Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24

Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25

Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26

Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27

Jubilant Life Sciences Plans Debt Offering For USD 250 Million 28

Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29

Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30

General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31

Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32

Jubilant Life Sciences Ltd, Key Competitors 33

Jubilant Life Sciences Ltd, Key Employees 34

Jubilant Life Sciences Ltd, Other Locations 35

Jubilant Life Sciences Ltd, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Jubilant Life Sciences Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company's product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical ingredients (APIs), solid dosage formulations, life science chemicals, nutritional products, fine ingredients, advance intermediates and crop science ingredients. It also provides contract manufacturing of sterile injectables and drug discovery and development services. The company caters its products and services to customers across India, North America, Canada, Europe and China. It owns and operates cGMP compliant manufacturing facilities, and research and development centers in India, the US and Canada. Jubilant is headquartered in Noida, Uttar Pradesh, India.

Jubilant Life Sciences Ltd (JUBILANT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Jubilant Pharma Plans to Acquire Pharma Business in US 14

Partnerships 15

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16

Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17

Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18

Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19

Licensing Agreements 20

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20

TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21

Equity Offering 22

Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22

Debt Offering 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24

Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25

Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26

Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27

Jubilant Life Sciences Plans Debt Offering For USD 250 Million 28

Asset Transactions 29

Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29

Acquisition 30

Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30

General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31

Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32

Jubilant Life Sciences Ltd-Key Competitors 33

Jubilant Life Sciences Ltd-Key Employees 34

Jubilant Life Sciences Ltd-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 38

Financial Announcements 38

Oct 22, 2018: Jubilant Life Sciences: Q2 & H1 'FY19 Results 38

Jul 27, 2018: Jubilant Life Sciences- Q1 FY 2019 Results-Jubilant Reports Strong Performance in Q1'FY19 Revenue at Rs. 2,079 Crore, up 34% YoY 42

May 09, 2018: Jubilant Life Sciences-Q4/ FY2018 Results- Jubilant Reports Strong Performance in Q4'FY18 Revenue at Rs. 2,252 crore, up 41% YOY; EBITDA at Rs. 481 crore, up 52% YOY PAT at Rs 155 crore 45

Jan 17, 2018: Jubilant Reports Record Performance In Q3 FY2018; Highest Ever Revenues And Profits Revenue At Rs. 2,068 Crore, Up 42% YOY and Ebitda at Rs. 431 Crore, Up 28% YOY Pat At Rs. 213 Crore, Up 78% YOY With 49

Oct 28, 2017: Jubilant Life Sciences: Q2/H1 FY2018 Results 53

Jul 18, 2017: Jubilant Life Sciences: Q1 FY2018 Result 57

Jul 18, 2017: Jubilant Reports Q1 FY2018 Revenue of Rs. 1,596 Crore, UP 10% YOY Pharma Segment Records Highest Ever Sales Ebitda of Rs. 344 Crore and Margins of 21.6%; Pat of Rs. 147 Crore 59

May 23, 2017: Jubilant Life Sciences Reports Total RevenueOf INR26.2 Billion In Fiscal 2017 61

Feb 07, 2017: Jubilant Reports Strong Performance In Q3 FY17; Sales At Rs. 1,492 Crore, Up By 7% YOY EBITDA At Rs. 337 Crore; Up 9% YOY With Margins Of 22.6%; PAT At Rs. 120 Crore 62

Corporate Communications 65

Oct 22, 2018: Jubilant Life Sciences announces appointment of directors 65

Jan 17, 2018: Jubilant Life Sciences: Changes in the Board of Directors 66

Legal and Regulatory 67

Mar 04, 2018: Jubilant Life Sciences: Commissioner of State Excise Cancelled License DS-1 License and Form-I License relating to the Distillery operations 67

Jan 25, 2017: Jubilant Life Sciences is now Responsible Care 14001: 2013 certified 68

Other Significant Developments 69

Jun 01, 2017: Jubilant Life Sciences Provides Update on Gajraula Manufacturing Unit 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Jubilant Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Jubilant Pharma Plans to Acquire Pharma Business in US 14

Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15

Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16

Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17

Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18

Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20

TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21

Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22

Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23

Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24

Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25

Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26

Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27

Jubilant Life Sciences Plans Debt Offering For USD 250 Million 28

Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29

Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30

General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31

Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32

Jubilant Life Sciences Ltd, Key Competitors 33

Jubilant Life Sciences Ltd, Key Employees 34

Jubilant Life Sciences Ltd, Other Locations 35

Jubilant Life Sciences Ltd, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Jubilant Life Sciences Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.